Vis enkel innførsel

dc.contributor.authorRamirez-Garrastacho, Manuel
dc.contributor.authorBajo-Santos, Cristina
dc.contributor.authorLine, Aija
dc.contributor.authorMartens-Uzunova, Elena S.
dc.contributor.authorde la Fuente, Jesus Martinez
dc.contributor.authorMoros, Maria
dc.contributor.authorSoekmadji, Carolina
dc.contributor.authorTasken, Kristin Austlid
dc.contributor.authorLlorente, Alicia
dc.date.accessioned2022-02-18T12:04:34Z
dc.date.available2022-02-18T12:04:34Z
dc.date.created2021-12-02T14:47:22Z
dc.date.issued2021-11-22
dc.identifier.citationBritish Journal of Cancer. 2021, .en_US
dc.identifier.issn0007-0920
dc.identifier.issn1532-1827
dc.identifier.urihttps://hdl.handle.net/11250/2980025
dc.description.abstractProstate cancer is a global cancer burden and considerable effort has been made through the years to identify biomarkers for the disease. Approximately a decade ago, the potential of analysing extracellular vesicles in liquid biopsies started to be envisaged. This was the beginning of a new exciting area of research investigating the rich molecular treasure found in extracellular vesicles to identify biomarkers for a variety of diseases. Vesicles released from prostate cancer cells and cells of the tumour microenvironment carry molecular information about the disease that can be analysed in several biological fluids. Numerous studies document the interest of researchers in this field of research. However, methodological issues such as the isolation of vesicles have been challenging. Remarkably, novel technologies, including those based on nanotechnology, show promise for the further development and clinical use of extracellular vesicles as liquid biomarkers. Development of biomarkers is a long and complicated process, and there are still not many biomarkers based on extracellular vesicles in clinical use. However, the knowledge acquired during the last decade constitutes a solid basis for the future development of liquid biopsy tests for prostate cancer. These are urgently needed to bring prostate cancer treatment to the next level in precision medicine.en_US
dc.description.sponsorshipThis work was supported by the TRANSCAN2-JTC2016 call (Project PROSCANEXO), The South-Eastern Norwegian Regional Health Authority, The Norwegian Cancer Society and The Research Council of Norway and the Latvian Council of Science grant No. lzp-2018/0269. CS was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the US Department of Defense Congressionally Directed Medical Research Program Prostate Cancer Research Program Idea Development Award [Number: W81XWH-16-1-0736].en_US
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofseriesBritish Journal of Cancer;126 (2022)
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectBiomarkersen_US
dc.subjectProstate canceren_US
dc.titleExtracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of researchen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© The Author(s) 2021en_US
dc.source.articlenumber126en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doihttps://doi.org/10.1038/s41416-021-01610-8
dc.identifier.cristin1963546
dc.source.journalBritish Journal of Canceren_US
dc.source.pagenumber331–350en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal